This database contains 102 studies, archived under the term: "alzheimer’s disease"
Click here to filter this large number of results.
Quality of life and Alzheimer’s disease: The influence of participation in a rehabilitation center
Quality of life is seldom explored in evaluations of therapeutic interventions in Alzheimer’s disease. Objective: To verify whether participation in a cognitive and functional rehabilitation program improves quality of life (QOL) among Alzheimer’s disease (AD) patients. Methods: 19 AD patients participated in this study, 12 of whom attended 24 multi-professional intervention sessions—the experimental group—whereas the […]
Longitudinal medication usage in Alzheimer disease patients
This study examined in detail patterns of cholinesterase inhibitors (ChEIs) and memantine use and explored the relationship between patient characteristics and such use. Patients with probable Alzheimer disease AD (n=201) were recruited from the Predictors Study in 3 academic AD centers and followed from early disease stages for up to 6 years. Random effects logistic […]
Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: A pilot study
Background and objective: Rivastigmine has been shown to be effective for patients with mild-to-moderate Alzheimer’s disease. Its effect on cognitive impairment after aneurysmal subarachnoid haemorrhage has not been previously studied. The aim of the study is to evaluate the efficacy and safety of rivastigmine 3 mg day over 12 weeks in patients with aneurysmal subarachnoid […]
Estimation and validation of a multiattribute model of Alzheimer disease progression
Objectives: To estimate and validate a multiattribute model of the clinical course of Alzheimer disease (AD) from mild AD to death in a high-quality prospective cohort study, and to estimate the impact of hypothetical modifications to AD progression rates on costs associated with Medicare and Medicaid services. Data and Methods: The authors estimated sex-specific longitudinal […]
Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for […]